1. Home
  2. PRAA vs STTK Comparison

PRAA vs STTK Comparison

Compare PRAA & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PRA Group Inc.

PRAA

PRA Group Inc.

SELL

Current Price

$20.27

Market Cap

710.0M

Sector

Finance

ML Signal

SELL

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$6.03

Market Cap

652.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAA
STTK
Founded
1996
2016
Country
United States
United States
Employees
170
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
710.0M
652.4M
IPO Year
2002
2020

Fundamental Metrics

Financial Performance
Metric
PRAA
STTK
Price
$20.27
$6.03
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
★ $15.40
AVG Volume (30 Days)
444.7K
★ 1.5M
Earning Date
11-02-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 53.02
EPS
★ 2.24
N/A
Revenue
★ $1,201,837,000.00
$1,000,000.00
Revenue This Year
$8.48
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.91
★ N/A
Revenue Growth
★ 7.83
N/A
52 Week Low
$10.25
$1.70
52 Week High
$22.55
$8.33

Technical Indicators

Market Signals
Indicator
PRAA
STTK
Relative Strength Index (RSI) 55.65 43.51
Support Level $18.32 $5.85
Resistance Level $21.39 $7.83
Average True Range (ATR) 0.89 0.47
MACD 0.01 -0.03
Stochastic Oscillator 70.95 32.44

Price Performance

Historical Comparison
PRAA
STTK

About PRAA PRA Group Inc.

PRA Group Inc is a specialty finance company engaged in the purchase, collection, and management of nonperforming loan portfolios. The majority of the loans it purchases are from credit originators who have chosen not to pursue, or have been unsuccessful in collecting, the full balance owed to them (Core accounts). To a lesser extent, the company also purchases loans in situations where the customer is involved in a bankruptcy or similar proceeding (Insolvency accounts). As part of an ancillary business, it also purchases and provides fee-based services for class action claims recoveries in the U.S. The company has two operating and reportable segments, comprised of its U.S. and European businesses. The majority of its revenue is generated from the United States.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: